General Information
Parexel Asthma 113844 4D
A first in human, double blind, placebo controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx0004, (a lyophilised formulation of Bifidobacterium breve), in subjects taking long-term control medication for their Asthma
| Protocol | |
|---|---|
| Identifier | |
| UID | 6e45cf30-d73a-433e-b578-7b01ee0566c7 |
| Status | Not Selected |
| Phase | 1/2 |
| Category | Asthma |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2022-06-01 17:17 |
| Last Updated | 2023-11-03 21:16 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | No | |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | - | No | |
| Recruiter | - | No | |
| Coordinator | - | No | |
| Regulatory | - | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Parexel |
|---|---|
| Division | Parexel |
| Team | Parexel |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Lightgray |
| Currency | - |
